Apotex gets FDA warning regarding contamination at Toronto plant

04/15/2010 | New York Times (tiered subscription model), The

The FDA sent a warning letter to generic-drug firm Apotex for failing to inform the agency about contamination involving an antihistamine and a diabetes drug produced at its plant in Toronto. The letter is the second time in less than a year that the FDA warned Apotex regarding manufacturing violations. The company did not respond to a newspaper's requests for comment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC